RTTNews | Dec 15, 2021 07:24AM EST

07:23 Wednesday, December 15, 2021 (RTTNews.com) - Nuvation Bio Inc. (NUVB) said the FDA has granted Fast Track designation to NUV-422, a cyclin-dependent kinase 2/4/6 inhibitor, for the treatment of patients with high-grade gliomas, including glioblastoma multiforme. NUV-422 is the company's lead investigational CDK2/4/6 inhibitor program.

David Hung, founder, president, and CEO of Nuvation Bio, said" "Enrollment is ongoing in our expanded phase 1/2 monotherapy study of NUV-422 for the treatment of adults with recurrent or refractory high-grade gliomas and solid tumors. We look forward to continuing to work closely with the FDA to expedite the development of NUV-422 with data from the phase 1 portion of the study, which is on track for 2022."

Read the original article on RTTNews ( https://www.rttnews.com/3249461/nuvation-bio-nuv-422-receives-fda-fast-track-designation.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved